Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	750 Milligram Xentuzumab (BI 836845)	6
Overall Study	STARTED	1000 Milligram Xentuzumab (BI 836845)	9
Overall Study	STARTED	1400 Milligram Xentuzumab (BI 836845)	6
Overall Study	Maximum Tolerated Dose (MTD) Set	750 Milligram Xentuzumab (BI 836845)	3
Overall Study	Maximum Tolerated Dose (MTD) Set	1000 Milligram Xentuzumab (BI 836845)	3
Overall Study	Maximum Tolerated Dose (MTD) Set	1400 Milligram Xentuzumab (BI 836845)	6
Overall Study	COMPLETED	750 Milligram Xentuzumab (BI 836845)	0
Overall Study	COMPLETED	1000 Milligram Xentuzumab (BI 836845)	3
Overall Study	COMPLETED	1400 Milligram Xentuzumab (BI 836845)	0
Overall Study	NOT COMPLETED	750 Milligram Xentuzumab (BI 836845)	6
Overall Study	NOT COMPLETED	1000 Milligram Xentuzumab (BI 836845)	6
Overall Study	NOT COMPLETED	1400 Milligram Xentuzumab (BI 836845)	6

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02145741/flow